Procoagulant snake venoms have differential effects in animal plasmas: Implications for antivenom testing in animal models
- 1 January 2016
- journal article
- research article
- Published by Elsevier in Thrombosis Research
- Vol. 137, 174-177
Abstract
No abstract availableKeywords
Funding Information
- NHMRC Program Grant (1055176)
- NHMRC Senior Research Fellowship (ID1061041)
This publication has 12 references indexed in Scilit:
- Current Treatment for Venom-Induced Consumption Coagulopathy Resulting from SnakebitePLOS Neglected Tropical Diseases, 2014
- Hump-nosed pit viper (Hypnale hypnale) envenoming causes mild coagulopathy with incomplete clotting factor consumptionClinical Toxicology, 2013
- Alpha neurotoxinsToxicon, 2013
- Factor deficiencies in venom‐induced consumption coagulopathy resulting from Australian elapid envenomation: Australian Snakebite Project (ASP‐10)Journal of Thrombosis and Haemostasis, 2010
- Endogenous thrombin potential as a novel method for the characterization of procoagulant snake venoms and the efficacy of antivenomToxicon, 2010
- Pre-clinical and preliminary dose-finding and safety studies to identify candidate antivenoms for treatment of envenoming by saw-scaled or carpet vipers (Echis ocellatus) in northern NigeriaToxicon, 2010
- A turbidimetric assay for the measurement of clotting times of procoagulant venoms in plasmaJournal of Pharmacological and Toxicological Methods, 2010
- Procoagulant Snake Toxins: Laboratory Studies, Diagnosis, and Understanding Snakebite CoagulopathySeminars in Thrombosis and Hemostasis, 2009
- Differences between human and rabbit coagulation factor X—implications for in vivo models of thrombosisThrombosis Research, 2002
- Species differences in anticoagulant and anti-Xa activity of DX-9065a, a highly selective factor Xa inhibitorThrombosis Research, 1995